CERo Therapeutics Holdings, Inc.
CERO
$9.46
$0.232.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -55.37% | -13.92% | -62.90% | -59.42% | -162.12% |
| Total Depreciation and Amortization | 1.13% | 4.13% | 39.77% | 108.26% | 313.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -109.07% | -4,726.95% | -99.22% | -52.37% | 13.10% |
| Change in Net Operating Assets | 359.82% | 240.10% | -77.93% | -114.86% | -134.53% |
| Cash from Operations | -30.19% | -123.07% | -137.14% | -168.50% | -324.77% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -107.41% | -104.49% | -104.34% |
| Total Debt Issued | -98.65% | -30.30% | -67.49% | -67.49% | 55.89% |
| Total Debt Repaid | -1,943.15% | -- | -576.46% | -- | -- |
| Issuance of Common Stock | 77.36% | 125,589.58% | 156,628.57% | 123,225.97% | 130,165.38% |
| Repurchase of Common Stock | -26,257.89% | -26,257.89% | -- | 100.00% | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,182.04% | -1,182.04% | -141,863.16% | 133.25% | -- |
| Cash from Financing | 66.90% | 2,301.22% | 108.86% | 107.06% | 105.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 135.72% | 115.55% | -100.26% | -102.97% | -104.28% |